This product is a RPMI 8226 B cell engineering tool based on the Nanoparticles (Hyaluronic acid/ RHAMM, CD44) delivery system and CRISPR-based (AAVS1-tracr RNA-Cas9-(Z)-4-Hydroxytamoxifen ) genome editor.
| Host Cell | RPMI 8226 |
| Target | CCR9 |
| Insert Clone | 9B1 |
| Safe Harbor Sites (SHS) | AAVS1 |
| gRNA | tracr RNA |
| Nuclease | Cas9 |
| Enhancer | (Z)-4-Hydroxytamoxifen |
| Targeting Strategy | pH responsive |
| Insertion sites | Nonhomologous target sites |
| Vehicles | Nanoparticles |
| Ligand/Receptor | Hyaluronic acid/ RHAMM, CD44 |
| Active Agents | DOX |
| Particle Size | 10-500 |
| Charge (mv) | <-25 |
| Total Atom Count | ~20,000,000 |
| Surface Atoms (%) | ~4 |
| Specific Surface Area (m2/g) | ~8 |
| Vector Type | AAV |
| Vector Name | BCpCDH1 |
| Targeting Diseases | Breast cancer; Colon cancer; Glioblastoma; Gastric cancer; Liver cancer |
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.